Caffeine intake during pregnancy and adverse outcomes: An integrative review
- PMID: 38042437
- DOI: 10.1016/j.reprotox.2023.108518
Caffeine intake during pregnancy and adverse outcomes: An integrative review
Abstract
Caffeine intake during pregnancy is common. Caffeine crosses the placenta, raising concerns about its possible deleterious effects on the developing embryo/fetus. Studies on this subject show conflicting results, and still there is no consensus on the recommended dose of caffeine during pregnancy. We performed an integrative review with studies from six databases, using broad MESH terms to allow the identification of publications that addressed the outcomes of caffeine use during pregnancy, with no date limit for publications, in English and Portuguese language. The research returned 16,192 articles. After removing duplicates, screening by title, abstract and full-text, we evaluated 257 and included 59 articles. We found association between caffeine intake and pregnancy loss, low birth weight, cardiac and genital anomalies, higher body mass, and neurodevelopmental and neurobehavioral outcomes. The effects were often dose dependent. No association with prematurity has been demonstrated, but one study showed a small reduction in gestational age with increasing doses of caffeine intake. Defining a safe dose for caffeine intake during pregnancy is a challenging task due to the heterogeneity in study designs and results, as well as the difficulty of reliably assessing the amount of caffeine consumed. In some studies, exposures below the recommended level of caffeine intake during pregnancy (200 mg/day), as suggested by the guidelines, were associated with pregnancy loss, low birth weight, cardiac and genital anomalies, higher body mass, and neurodevelopmental and neurobehavioral outcomes. Well-designed studies with reliable quantification of caffeine intake are needed to assess the safety of low doses during pregnancy.
Keywords: Coffee; Gestation; Neonates; Obstetric recommendations; Tea; Teratogens.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
Grants and funding
- #88887.502993/2020–00/Brazilian Federal Agency for Support and Evaluation of Graduate Education (in Portuguese, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES)
- #149066/2022–8/Brazilian National Council for Scientific and Technological Development (in Portuguese, Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq)
LinkOut - more resources
Full Text Sources
Medical